harmine
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2020 (NCT04716335)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(c1)[nH]c1c(C)nccc12- Mol. weight
- 212.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL269538 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06252506 | Phase 1 | Jan 22, 2024 | University of Bern, University of Zurich |
| NCT05780216 | Early Phase 1 (Phase 1) | Feb 20, 2023 | University of Freiburg, University of Zurich |
| NCT05526430 | Phase 1 | Sep 13, 2022 | Icahn School of Medicine at Mount Sinai, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04716335 | Early Phase 1 (Phase 1) | Dec 1, 2020 | University of Basel, University of Zurich |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Zurich | Academic/Hospital | 3 | 2 | 1 | 2020 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2022 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Freiburg | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1